FDA Approved Pluvicto for Metastatic Prostate Cancer

The treatment uses theranostics to target and deliver radiation to prostate cancer cells.

Updated on Sept. 29, 2026 in Cancer

FDA Approved Pluvicto for Metastatic Prostate Cancer

Live Poll

Do you trust targeted cancer therapies more than traditional chemotherapy for managing serious illness?

In July 2026, the FDA approved Pluvicto for the treatment of newly diagnosed metastatic prostate cancer. This therapy utilizes a theranostics approach that combines diagnostic imaging with targeted radiation to identify and treat cancer cells.

Why it matters

Theranostics provides a higher degree of precision for identifying and attacking cancer cells compared to conventional treatment methods. This targeted approach allows medical professionals to deliver internal radiation directly to the disease while sparing healthy tissue.

Pluvicto treatment consists of up to six sessions administered via IV injection every six weeks. The therapy is only effective for patients who possess the specific PSMA protein.

The players

FDA

The FDA is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.

The details

The treatment works by using a PSMA PET scan to identify active prostate cancer cells by targeting specific proteins. Once identified, the therapy delivers internal radiation directly to those cells through a scheduled IV injection process.

The FDA approved Pluvicto for newly diagnosed metastatic prostate cancer in July 2026.
Patients receive Pluvicto IV injections at intervals of every six weeks.

Deeper Dive

The clinical adoption of Pluvicto follows established FDA drug approval protocols for expanding the indications of targeted oncology therapies. This integration of theranostics marks a shift toward highly personalized diagnostic-driven cancer treatments.

Patients undergoing this treatment should prepare for a course of up to six sessions requiring clinical visits every six weeks. Common side effects that may impact daily routines include fatigue, dry mouth, and changes to blood counts.

The takeaway

Patients should consult with their oncologists to determine if they possess the required PSMA protein for this therapy. Integrating diagnostic imaging with treatment allows for a more personalized approach to managing metastatic cancer.